뉴스
GENIXCURE selects 'AD gene therapy' government task
2021-01-11
Selection of 'ANL-101' Dementia Treatment Development Task
ANL-101, a candidate substance for GENIXCURE's Alzheimer's (AD) gene therapy, was selected as a task for the government's Dementia Overcoming Research and Development Project to develop dementia treatments. This support project is the first support project since the launch of the project group this year.
GENIXCURE announced on the 28th that the ANL-101 pipeline has been selected as a task in the non-clinical sector in the field of treatment development for dementia overcoming research and development projects organized by the Ministry of Health and Welfare and the Ministry of Science and ICT. The Dementia Overcoming Research and Development Project is a research and development support project for the prevention, diagnosis, and treatment of dementia under the "National Dementia Research and Development Mid- to Long-Term Strategy."
GENIXCURE said its goal is to develop ANL-101 as a drug that enables treatment with a single administration through the control of miRNA. He also explained that he received good reviews for the innovation and creativity of the technology in the selection of this task.
GENIXCURE is an R&D company that was established in 2019 based on the research results of CEO Kim keetae, who investigated the correlation between miRNA and aging. The main pipeline for new drug development is the development of treatments for CNS diseases and rare genetic diseases such as Alzheimer's, mild cognitive impairment, Parkinson's disease, and epilepsy.
In GENIXCURE, COO Moon Hong-sung is in charge of management and CSO Kim Keetae is in charge of research and development. In addition, POSCO Technology Investment raised 2 billion won through redeemable convertible preferred stocks (RCPS) in October and is currently conducting Series A.
"We are proud that the government has been selected as one of the first support projects of the newly established Dementia Overcoming Research and Development Project to strategically overcome dementia," an official from GENIXCURE said. "We will focus more on realizing the value of 'beautiful aging and healthy longevity' pursued by the company."